Alterity Therapeutics Ltd ADR ATHE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ATHE is a good fit for your portfolio.
News
-
Alterity Therapeutics to Present at MST Financial Webinar
-
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
-
Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy
-
Alterity Therapeutics to Present at the MST Access ‘Hidden Gems in Life Sciences’ Webinar
-
Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study
-
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
-
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
-
Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxia
Trading Information
- Previous Close Price
- $1.60
- Day Range
- $1.57–1.61
- 52-Week Range
- $1.55–5.41
- Bid/Ask
- $1.59 / $1.61
- Market Cap
- $14.26 Mil
- Volume/Avg
- 6,536 / 40,699
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 11
Valuation
|
Metric
|
ATHE
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
ATHE
|
|---|---|
Quick Ratio | 5.58 |
Current Ratio | 6.17 |
Interest Coverage | — |
Quick Ratio
ATHE
Profitability
|
Metric
|
ATHE
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ATHE
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Syjdjcdwl | Qbbxb | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Gvqdrrtnr | Fkzpmr | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ntzjkny | Rwhhrh | $117.3 Bil | |||
| Moderna Inc
MRNA
| Lmfmlvcjb | Pndx | $46.1 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mztxdhkq | Bjbbwt | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Xvfkkvq | Lfsdl | $28.8 Bil | |||
| BioNTech SE ADR
BNTX
| Xbzbkyq | Vhxg | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Wsgztdcr | Bkdpzq | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Pcxbdkz | Zxxk | $14.9 Bil | |||
| Incyte Corp
INCY
| Tnsbnhpb | Hmwszm | $13.5 Bil |